<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35725782</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>32</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.</ArticleTitle><Pagination><StartPage>4424</StartPage><EndPage>4431</EndPage><MedlinePgn>4424-4431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.05.090</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00748-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Symptoms of post-acute sequelae of COVID-19 (PASC) may improve following SARS-CoV-2 vaccination. However few prospective data that also explore the underlying biological mechanism are available. We assessed the effect of vaccination on symptomatology of participants with PASC, and compared antibody dynamics between those with and without PASC.</AbstractText><AbstractText Label="METHODS">RECoVERED is a prospective cohort study of adult patients with mild to critical COVID-19, enrolled from illness onset. Among participants with PASC, vaccinated participants were exact-matched 1:1 on age, sex, obesity status and time since illness onset to unvaccinated participants. Between matched pairs, we compared the monthly mean numbers of symptoms over a 3-month follow-up period, and, using exact logistic regression, the proportion of participants who fully recovered from PASC. Finally, we assessed the association between PACS status and rate of decay of spike- and RBD-binding IgG titers up to 9&#xa0;months after illness onset using Bayesian hierarchical linear regression.</AbstractText><AbstractText Label="FINDINGS">Of 349 enrolled participants, 316 (90.5%) had &#x2265;3&#xa0;months of follow-up, of whom 186 (58.9%) developed PASC. Among 36 matched pairs with PASC, the mean number of symptoms reported each month during 3&#xa0;months of follow-up were comparable between vaccinated and unvaccinated groups. Odds of full recovery from PASC also did not differ between matched pairs (OR 1.57 [95%CI 0.46-5.84]) within 3&#xa0;months after the matched time-point. The median half-life of spike- and RBD-binding IgG levels were, in days (95%CrI), 233 (183-324) and 181 (147-230) among participants with PASC, and 170 (125-252) and 144 (113-196) among those without PASC, respectively.</AbstractText><AbstractText Label="INTERPRETATION">Our study found no strong evidence to suggest that vaccination improves symptoms of PASC. This was corroborated by comparable spike- and RBD-binding IgG waning trajectories between those with and without PASC, refuting any immunological basis for a therapeutic effect of vaccination on PASC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wynberg</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands. Electronic address: ewijnberg@ggd.amsterdam.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Alvin X</ForeName><Initials>AX</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; Stichting HIV Monitoring, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Willigen</LastName><ForeName>Hugo D G</ForeName><Initials>HDG</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verveen</LastName><ForeName>Anouk</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebbink</LastName><ForeName>Romy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Straten</LastName><ForeName>Karlijn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kootstra</LastName><ForeName>Neeltje</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gils</LastName><ForeName>Marit J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenstra</LastName><ForeName>Tjalling</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Menno D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bree</LastName><ForeName>Godelieve J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECoVERED Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Therapeutic vaccine</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.B. received a grant from ANRS in the past 36 months and participated on the Data Safety Monitoring Board or Advisory Board for ZonMw for a study conducted by the Amsterdam University Medical Centers, location Amsterdam Medical Center. G.d.B. served as a paid member of the scientific advisory board of ExeVir in the past 36 months, and is a patent holder of INV 2020-039 both through their institution. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>23</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35725782</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pii">S0264-410X(22)00748-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wynberg E., van Willigen H.D.G., Dijkstra M., et al. Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clin Infect Dis. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522402</ArticleId><ArticleId IdType="pubmed">34473245</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., et al. Characterising long COVID: a living systematic review. BMJ Global Health. 2021;6(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization (WHO) clinical case definition working group on post COVID-19 condition; 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Milne A., Samms E., Stadon L., Maskell N.A., Hamilton F.W. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. Ann Intern Med. 2021;174(9):1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-TP, Elodie; Saldanha, Julia; Pane, Isabelle; Ravaud, Philippe. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France. SSRN Pre-Print; 2021.</Citation></Reference><Reference><Citation>Cervia C., Zurbuchen Y., Taeschler P., Ballouz T., Menges D., Hasler S., et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC. Clinical Data Collection &#x2013; The COVID-19 Case Report Forms (CRFs). Available at: https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/. Accessed 18 Feb.</Citation></Reference><Reference><Citation>Rijksoverheid. Aanpak coronavaccinatie in Nederland. Available at: https://www.rijksoverheid.nl/onderwerpen/coronavirus-vaccinatie/aanpak-coronavaccinatie. Accessed 10 Nov.</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 Clinical management: living guidance; 2021 25 January 2021.</Citation></Reference><Reference><Citation>Brouwer PA-O, Caniels TA-OX, van der Straten KA-O, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. (1095-9203 (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299281</ArticleId><ArticleId IdType="pubmed">32540902</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gils MJ, van Willigen HDG, Wynberg E, et al. A Single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668345</ArticleId><ArticleId IdType="pubmed">35103254</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer P.J.M., Brinkkemper M., Maisonnasse P., Dereuddre-Bosquet N., Grobben M., Claireaux M., et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021;184(5):1188&#x2013;1200.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834972</ArticleId><ArticleId IdType="pubmed">33577765</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. LID - 10.1084/jem.20201181 [doi] LID - e20201181. (1540-9538 (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacus S.M., King G., Porro G. Causal Inference without Balance Checking: Coarsened Exact Matching. Political Analysis. 2012;20(1):1&#x2013;24.</Citation></Reference><Reference><Citation>Salvatier J., Wiecki T.V., Fonnesbeck C. Probabilistic programming in Python using PyMC3. PeerJ Computer. Science. 2016;2:e55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10495961</ArticleId><ArticleId IdType="pubmed">37705656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Changes in the trajectory of Long Covid symptoms following COVID-19 vaccination: community-based cohort study. medRxiv; 2021: 2021.12.09.21267516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. medRxiv; 2021: 2021.10.26.21265508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky JP, Govindarajulu U, Bagiella E, et al. Association of Vaccination with the Persistence of Post-COVID Symptoms. (1525-1497 (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After. medRxiv; 2021: 2021.11.17.21263608.</Citation></Reference><Reference><Citation>Jab&#x142;o&#x144;ska K., Aball&#xe9;a S., Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021;198:230&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413007</ArticleId><ArticleId IdType="pubmed">34482101</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27(9):1607&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>